Drugs News and Research

RSS

Isis Pharmaceuticals starts Phase 1 clinical study of ISIS-PKKRx to treat patients with HAE

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it initiated a Phase 1 clinical study of ISIS-PKKRx. ISIS-PKKRx is an antisense drug in development to treat patients with hereditary angioedemia (HAE).

21 May 2014

Substance from pine bark is a potential source for treating melanoma

A substance that comes from pine bark is a potential source for a new treatment of melanoma, according to Penn State College of Medicine researchers.

21 May 2014

Edison Pharmaceuticals' EPI-743 granted orphan designation for Leigh syndrome in Japan

Edison Pharmaceuticals has announced that the Japanese Ministry of Health, Labor and Welfare (MHLW) has granted Orphan Designation to EPI-743 for the treatment of Leigh syndrome.

21 May 2014

Space Station science: Microgravity on human thyroid carcinoma cells

The multi-national efforts that go into research aboard the International Space Station show that working together can yield results with universal benefits.

21 May 2014

The future of high throughput screening: an interview with Mark Wigglesworth, Director High Throughput Screening, AstraZeneca

Quoting Mike Snowden (VP & Head of Discovery Sciences, AstraZeneca), “it’s where biology meets chemistry”. It’s where for the first time a target protein can be probed for novel molecules that modulate its function, of course we want to do this to prove a hypothesis that these proteins are drug targets with the potential to deliver innovative medicines.

20 May 2014

Aradigm receives QIDP designation for its inhaled antibiotic candidate, Pulmaquin

Aradigm Corporation (the "Company") today announced that the U.S. Food and Drug Administration (FDA) has designated the Company's lead inhaled antibiotic candidate, Pulmaquin®, as a Qualified Infectious Disease Product (QIDP).

20 May 2014

Recruiting more Hispanics to cancer clinical trials crucial to reducing health disparities

Hispanics are the fastest-growing demographic group in the United States, and they suffer from major health disparities, including higher rates of cancers of the cervix, stomach and liver.

20 May 2014

Sanofi presents Phase II trial results for investigational vaccine for prevention of CDI

Sanofi Pasteur, the vaccines division of Sanofi, presented Phase II (H-030-012) trial results for an investigational vaccine for the prevention of Clostridium difficile infection at the 114th General Meeting of the American Society for Microbiology.

20 May 2014

Existing pharmaceutical drugs may offer effective therapies against MERS

A series of research articles published ahead of print in the journal Antimicrobial Agents and Chemotherapy have identified a number of existing pharmaceutical drugs and compounds under development that may offer effective therapies against Middle East Respiratory Syndrome (MERS).

20 May 2014

Novel drug for patients with inoperable CTEPH shows improvement in international trial

After a year of being treated with a novel drug, patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) and those with persistent or recurrent pulmonary hypertension after an operation for the disease showed sustained improvement in a multicenter, international trial presented at the 2014 American Thoracic Society International Conference.

20 May 2014

Viewpoints: Pence on Medicaid expansion; Jindal on Obamacare repeal efforts; 'long-shot' lawsuits

From the beginning of my tenure as governor in 2013, we have been saying no to Obamacare in Indiana.

20 May 2014

Highlights: Nurse practitioners fight for autonomy in Texas; Ohio physician assistant prescriptions; drug options in Colo.

A selection of health policy stories from Texas, Ohio, Colorado, North Carolina, Massachusetts, Alabama, Connecticut and Kansas.

20 May 2014

GSK reports positive results from Incruse Ellipta and Advair Diskus combination therapy in COPD patients

GlaxoSmithKline plc today presented data at the American Thoracic Society (ATS) from a late-stage clinical study.

20 May 2014

Orexo US partners with inVentiv Health to market Zubsolv sublingual tablets in the US

Orexo AB announces a new partnership between Orexo US, Inc. and inVentiv Health for the commercialization of Zubsolv in the US.

20 May 2014

Elotuzumab granted Breakthrough Therapy Designation for treatment of multiple myeloma

Bristol-Myers Squibb Company and AbbVie today announced that the U.S. Food and Drug Administration (FDA) has granted elotuzumab, an investigational humanized monoclonal antibody, Breakthrough Therapy Designation for use in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma in patients who have received one or more prior therapies.

20 May 2014

New technique can predict which stroke victims will benefit from clot-busting drugs

Johns Hopkins researchers say they have developed a technique that can predict — with 95 percent accuracy — which stroke victims will benefit from intravenous, clot-busting drugs and which will suffer dangerous and potentially lethal bleeding in the brain.

20 May 2014

TSRI chemists develop correct structure of highly promising anticancer compound

Chemists at The Scripps Research Institute (TSRI) have determined the correct structure of a highly promising anticancer compound approved by the U.S. Food and Drug Administration (FDA) for clinical trials in cancer patients.

20 May 2014

Biovision provides list of businesses, projects selected for Investor Conference and Catalyzer sessions

Biovision, the annual forum on future-oriented research in life sciences, today announces the list of biotech and medtech companies and projects selected for the Investor Conference and Catalyzer sessions. Awards will be presented during the closing ceremony.

20 May 2014

Study compares effectiveness of duloxetine and fluoxetine in children with MDD

Two studies of the anti-depressive drug duloxetine, a serotonin-norepinephrine reuptake inhibitor (SNRI), compared its effectiveness and safety to either fluoxetine or placebo in children and adolescents with major depressive disorder (MDD).

20 May 2014

CTR1 may be required for successful platinum-based therapy in NSCLC

Tumours with undetectable levels of the copper transporter CTR1 have a significantly reduced response to platinum-based chemotherapy for non-small-cell lung cancer, study findings indicate.

19 May 2014

Drugs News and Research

Isis Pharmaceuticals starts Phase 1 clinical study of ISIS-PKKRx to treat patients with HAE

Substance from pine bark is a potential source for treating melanoma

Edison Pharmaceuticals' EPI-743 granted orphan designation for Leigh syndrome in Japan

Space Station science: Microgravity on human thyroid carcinoma cells

The future of high throughput screening: an interview with Mark Wigglesworth, Director High Throughput Screening, AstraZeneca

Aradigm receives QIDP designation for its inhaled antibiotic candidate, Pulmaquin

Recruiting more Hispanics to cancer clinical trials crucial to reducing health disparities

Sanofi presents Phase II trial results for investigational vaccine for prevention of CDI

Existing pharmaceutical drugs may offer effective therapies against MERS

Novel drug for patients with inoperable CTEPH shows improvement in international trial

Viewpoints: Pence on Medicaid expansion; Jindal on Obamacare repeal efforts; 'long-shot' lawsuits

Highlights: Nurse practitioners fight for autonomy in Texas; Ohio physician assistant prescriptions; drug options in Colo.

GSK reports positive results from Incruse Ellipta and Advair Diskus combination therapy in COPD patients

Orexo US partners with inVentiv Health to market Zubsolv sublingual tablets in the US

Elotuzumab granted Breakthrough Therapy Designation for treatment of multiple myeloma

New technique can predict which stroke victims will benefit from clot-busting drugs

TSRI chemists develop correct structure of highly promising anticancer compound

Biovision provides list of businesses, projects selected for Investor Conference and Catalyzer sessions

Study compares effectiveness of duloxetine and fluoxetine in children with MDD

CTR1 may be required for successful platinum-based therapy in NSCLC

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News